



Universiteit
Leiden
The Netherlands

Towards a patient-driven approach to adverse events of targeted agents in oncology

Boers, C.B.

Citation

Boers, C. B. (2019, September 4). *Towards a patient-driven approach to adverse events of targeted agents in oncology*. Retrieved from <https://hdl.handle.net/1887/77519>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/77519>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/77519> holds various files of this Leiden University dissertation.

Author: Boers, C.B.

Title: Towards a patient-driven approach to adverse events of targeted agents in oncology

Issue Date: 2019-09-04

10 | About the author

Curriculum Vitae

Christine Boers-Doets was born April 19th 1968 in Rheinberg, Germany. She currently lives with her husband Edwin and her three children Esmée, Danique, and Loran, in Wormer, The Netherlands.

After finishing secondary school at the Realschule in Rheinkamp, Germany, she moved to the Netherlands to complete class 4 & 5 of the HAVO in Venray. After finishing secondary school, she studied nursing at the HBO-V in Eindhoven and completed this education in 1992 in Alkmaar, The Netherlands. She received her bachelor degree in 1988 and her nursing degree in 1992. Besides being full-time employed as a nurse at the St Lucas Hospital in Amsterdam, The Netherlands, she finished her master degree in Health Sciences from 1993 to 1997 at the University of Utrecht. From 1997 till 2012 Christine has worked as clinical nurse specialist and research coordinator at the Waterland Hospital in Purmerend, The Netherlands.

In 2012 she founded the Impaqtt Foundation to be able to complete her research program with special attention to finalizing the COMTT and the BeCet trial on the one hand and raising awareness and funding for more next generation patient-driven studies and patient support projects on the other hand. In 2013 she founded her own company *CancerMed*. She is an active member of MASCC, the Multinational Association of Supportive Care in Cancer. With her research, teaching, and mentoring she supports pharmaceutical companies, policymakers, universities, hospitals, homecare organizations, footcare specialists, and patient advocacies on how to help patients conquer cancer. Targeted anticancer therapies, inclusive endocrine therapies and immuno-oncology, have her upmost attention.

Besides being fulltime employed, Christine started her PhD journey in 2006 at the Radboud University Nijmegen, The Netherlands. In 2008, the Leiden University Medical Center (LUMC), The Netherlands became involved. In 2010, she moved her PhD project entirely to the LUMC, where she completed her PhD in 2019.

List of publications

- Ouwerkerk J, **Boers-Doets CB**: Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. *Eur J Oncol Nurs*. 2010;14(4):337-49. Epub 2010 May 23
- Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, **Boers-Doets CB**, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. *Int J Dermatol*. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x.
- Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. *Support Care Cancer*. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1.
- Boers-Doets CB**, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H. Oral AEs associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. *Oncologist*. 2012;17(1):135-44. doi: 10.1634/theoncologist.2011-0111. Epub 2011 Dec 29.
- Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, **Boers-Doets C**, Molassiotis A: Strategies for assessing and managing the AEs of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group. *Eur J Oncol Nurs*. 2012 Apr;16(2):172-84. Epub 2011 Jun 8.
- Boers-Doets CB**, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. *Eur J Oncol Nurs*. 2013 Dec;17(6):802-7. doi: 10.1016/j.ejon.2013.03.004. Epub 2013 Apr 6.
- Boers-Doets CB**, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous AEs. *Support Care Cancer*. 2013 Jul;21(7):1919-26. doi: 10.1007/s00520-013-1752-4. Epub 2013 Feb 17.
- Wong RK, Bensadoun RJ, **Boers-Doets CB**, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. *Support Care Cancer*. 2013 Oct;21(10):2933-48. doi: 10.1007/s00520-013-1896-2. Epub 2013 Aug 14.
- Elting LS, Chang YC, Parelkar P, **Boers-Doets CB**, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, Bossi P, Escalante C, Brennan MT; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. *Support*

- Care Cancer*. 2013 Nov;21(11):3243-54. doi: 10.1007/s00520-013-1821-8. Epub 2013 May 2.
- Boers-Doets CB**, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H. Mammalian target of rapamycin inhibitor-associated stomatitis. *Future Oncol*. 2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141.
- De Wit M, **Boers-Doets CB**, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A, Cremolini C. Prevention and management of AEs related to regorafenib. *Support Care Cancer*. 2014 Mar;22(3):837-46. doi: 10.1007/s00520-013-2085-z. Epub 2013 Dec 14.
- Bryce J, **Boers-Doets CB**. Non-rash dermatologic AEs related to targeted therapies. *Semin Oncol Nurs*. 2014 Aug;30(3):155-68. doi: 10.1016/j.soncn.2014.05.003.
- Clabbers JM, **Boers-Doets CB**, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJ, Kaptein AA. Xerosis and pruritus as major EGFR-associated AEs. *Support Care Cancer*. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.
- Ruiz JN, Belum VR, **Boers-Doets CB**, Kamboj M, Babady NE, Tang YW, Valdez TA, Lacouture ME. Nasal vestibulitis due to targeted therapies in cancer patients. *Support Care Cancer*. 2015 Aug;23(8):2391-8. doi: 10.1007/s00520-014-2580-x. Epub 2015 Jan 22.
- Chan A, Cameron MC, Garden B, **Boers-Doets CB**, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. A systematic review of patient-reported outcome instruments of dermatologic AEs associated with targeted cancer therapies. *Support Care Cancer*. 2015 Aug;23(8):2231-44. doi: 10.1007/s00520-014-2564-x. Epub 2015 Jan 7.
- Peterson DE, **Boers-Doets CB**, Bensadoun RJ, Herrstedt J; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v139-51. doi: 10.1093/annonc/mdv202. Epub 2015 Jul 4.
- Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, **Boers-Doets CB**, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. *Ann Oncol*. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.

11 | Acknowledgements

I have learned much from many people in many different areas. During interviews, consultancy, lectures, workshops, trainings, face-to-face conversations, discussions, comments on trainings, workshops, and mentoring sessions, I received many feedbacks that gave me direction for my research program. There are a number of people I want to mention separately:

My supervisors and thesis (co-)advisors Hans Gelderblom, Ad A. Kaptein, Joel B. Epstein, Mario E. Lacouture, Johan W.R. Hans Nortier, Koos J.M. van der Hoeven, Theo van Achterberg, Ruud Uitterhoeve, and Jan A.C. Brakenhoff: Thank you so much for making my PhD happen.

My paranymphs and friends Natascha Schrama and Jan Ouwerkerk: Thank you so much for your continuous support and friendship.

My patients and participants in the FACT-EGFRI-18 validation, BeCet, and COMTT study: Thank you so much for the in-depth information you provided and the insight you gave me.

My sparring partners at Amgen, AstraZeneca, Baxalta/Shire, Bayer, Becton, Dickinson & Company (BD), Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Eusa Pharma, Galera Therapeutics, GlaxoSmithKline, Helsinn, Ipsen, Lifestream Pharma, Merck, Merck Sharp & Dohme (MSD), Nordic Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, and Takeda: Thank you so much for sharing your resources, partnering and your intellectual support.

My co-authors Anniek Arends, René-Jean Bensadoun, Jason Bredle, Julia M.K. Clabbers, Nielka van Erp, Helen Gall, Jørn Herrstedt, Rajesh V. Lalla, Richard M. Logan, Douglas E. Person, Judith E. Raber-Durlacher, Theo Stijnen, Nathaniel S. Treister, and Diede Wiersma: Thank you so much for the impactful work we have performed together.

My data managers Rianne Boers, Karin Boers, Karin Kremer, Sylvia van Leeuwen, and Sylvia Loos: Thank you so much for collecting and checking data of the BeCet and COMTT trial and so much more.

My sport mates Karin Kremer, Gera Krijt, and Miranda Kielen: Thank you so much for supporting me on my journey.

My family, friends, clients, and colleagues which I can't list here separately because of the limited space: Thank you so much for your wise words, and support.

My parents and sisters Ina van der Ende, Arie Boers, Rianne Boers, Karin Boers, and Anja van der Ende: Thank you so much for being my support system.

My husband Edwin and my kids Esmée, Danique, and Loran Doets: Thank you so much for supporting and missing me throughout the 12 years I have been working towards my PhD.

Thank you so much all of you. Together we have made it happen.